Company Overview of Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company’s product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is u...
1550 East Gude Drive
Rockville, MD 20850
Founded in 2005
Key Executives for Supernus Pharmaceuticals, Inc.
Founder, Chief Executive Officer, President, Secretary and Director
Total Annual Compensation: $523.4K
Chief Financial Officer and Vice President
Total Annual Compensation: $330.5K
Chief Medical Officer and Executive Vice President of Research & Development
Total Annual Compensation: $356.4K
Chief Scientific Officer and Senior Vice President of Intellectual Property
Total Annual Compensation: $337.4K
Senior Vice President of Sales and Marketing
Total Annual Compensation: $291.6K
Compensation as of Fiscal Year 2015.
Supernus Pharmaceuticals, Inc. Key Developments
Supernus Pharmaceuticals, Inc. Receives Final FDA Approval for Trokendi XR® for Migraine Prophylaxis in Adults and Adolescents
Apr 5 17
Supernus Pharmaceuticals, Inc. announced that the Food and Drug Administration (FDA) has granted final approval to the company’s Supplemental New Drug Applications (sNDAs) requesting a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults and adolescents 12 years and older. Supernus was granted tentative approval of one of the two sNDAs in August 2016, with final approval subject to the pediatric exclusivity of the innovator’s drug in the adolescent population, which expired March 28, 2017. Based on IMS prescription data, Topiramate is the most prescribed drug for the treatment of migraine prophylaxis with more than 9 million prescriptions annually. This represents approximately 50% of all IMS prescriptions written for migraine prophylaxis.
Supernus Pharmaceuticals, Inc. Announces Settlement with Actavis on Trokendi XR Patent Litigation
Mar 7 17
Supernus Pharmaceuticals, Inc. announced that it has entered into a binding term sheet with Actavis Laboratories, FL, Inc. involving the ongoing patent litigation regarding Actavis’ Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of Supernus’ Trokendi XR (extended-release topiramate) capsules. The binding term sheet permits Actavis to begin selling a generic version of Trokendi XR® on January 1, 2023, or earlier under certain circumstances. The binding term sheet will be submitted to the applicable governmental agencies. Supernus intends to continue its vigorous enforcement of its patent rights for Trokendi XR. Patent protection for Trokendi XR® expires no earlier than 2027.
Supernus Pharmaceuticals Settles with Zydus Pharmaceutical & Cadila Healthcare over Litigation Relating to Trokendi Capsules
Mar 6 17
Supernus Pharmaceuticals announced that it entered into a settlement agreement with Zydus Pharmaceutical (USA) and Cadila Healthcare. The deal involves an ongoing patent litigation regarding Zydus' abbreviated new drug application (ANDA) seeking approval to market generic versions of Supernus' Trokendi XR capsules. The settlement permits Zydus to begin selling a generic version on Jan. 1, 2023, or earlier under certain circumstances.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|